GSK (NYSE:GSK) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $49.57 and traded as low as $47.36. GSK shares last traded at $48.7080, with a volume of 8,115,867 shares changing hands.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Third-quarter results exceeded expectations: Adjusted earnings were approximately $1.47 per ADR, above the $1.40 consensus, while revenue rose about 4% year over year to roughly $11.8 billion. GSK maintained its full-year targets. GSK beats third-quarter profit estimates, keeps annual targets
• Positive Sentiment: Specialty medicines remained the growth engine: HIV, oncology and respiratory products delivered strong or double-digit growth, offsetting weaker vaccines and broadly flat general-medicine sales. GSK Sales Get Boost From Specialty Medicines
• Positive Sentiment: Oncology expansion offers longer-term upside: GSK plans to nearly double the number of cancer drugs in trials next year following recent dealmaking. The company also expects another oncology approval, potentially broadening its growth pipeline. GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
• Neutral Sentiment: Hepatitis B launch preparation: GSK is preparing a concentrated U.S. launch for Hibsago, its newly approved hepatitis B vaccine, which could provide a future boost to the vaccine portfolio but will require successful commercial execution. Hibsago prepares for U.S. hepatitis B launch
• Negative Sentiment: Vaccine weakness overshadowed the earnings beat: Declining adult demand led vaccine revenue to miss expectations, raising concerns about the pace of recovery in a historically important business. GSK shares slide after weaker vaccine sales
• Negative Sentiment: Cost and pipeline concerns persist: Mounting costs and questions about the strength of GSK’s future pipeline reduced the market’s enthusiasm for the solid quarter, leaving investors focused on whether specialty-drug growth can sustainably offset vaccine pressure. GSK shares decline as weaker sales and mounting costs concern investors

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GSK. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and set a $55.90 price objective for the company. in a research report on Thursday. Wolfe Research began coverage on GSK in a research note on Friday, October 9th. They set an "outperform" rating and a $70.00 target price for the company. HSBC reissued a "hold" rating on shares of GSK in a research note on Thursday, September 10th. Finally, Deutsche Bank Aktiengesellschaft restated a "neutral" rating on shares of GSK in a report on Tuesday, September 29th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of "Hold" and a consensus target price of $55.48.

GSK Stock Performance

The stock has a market capitalization of $98.52 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The stock's 50 day moving average is $49.57 and its two-hundred day moving average is $52.35.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%. The company's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. Analysts expect that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GSK. Mondrian Investment Partners LTD raised its position in GSK by 1.1% in the 3rd quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company's stock valued at $239,210,000 after buying an additional 55,116 shares during the last quarter. NewEdge Advisors LLC boosted its position in GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company's stock worth $49,986,000 after acquiring an additional 852,437 shares during the last quarter. Foster Victor Wealth Advisors LLC boosted its position in GSK by 5.8% during the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company's stock worth $21,674,000 after acquiring an additional 23,934 shares during the last quarter. Sound Income Strategies LLC boosted its position in GSK by 2.7% during the 3rd quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company's stock worth $16,209,000 after acquiring an additional 9,218 shares during the last quarter. Finally, Waverly Advisors LLC raised its holdings in shares of GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company's stock valued at $15,233,000 after purchasing an additional 270,863 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.